NTI — Neurotech International Share News
0.000.00%
Last trade - 00:00- AU$25.04m
- AU$22.65m
- AU$0.04m
Brief: Neurotech International Appoints Mark Davies As Executive Chairman
Brief: Neurotech International Receives Binding Commitments For Around A$4.50 Million In Placement At A$0.014 Per Share
Australia's Neurotech International slips to a month low on discounted placement
Brief: Neurotech International Requests Trading Halt
Brief: Neurotech International Says US FDA Clears IND For NTI164
Australia's Neurotech International rises on US FDA nod for neurological disorders drug
Brief: Neurotech International Says USPTO Sends Notices Of Allowance For Two NTI Patent Applications
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Australia's Neurotech International slips most since April on discounted placement
Brief: Neurotech International Receives A$4 Million Placement Commitments
Brief: Neurotech International Requests Trading Halt Pending Capital Raising Announcement
Brief: Neurotech International Gets US FDA Rare Pediatric Disease Designation For NTI164
Australia's Neurotech International jumps as US FDA grants rare disease status for drug candidate
Brief: Neurotech International Posts FY Loss Attributable A$10.6 Million
Australia's Neurotech gains as Rett Syndrome drug gets 'orphan' tag from EU
Brief: Neurotech International Says European Commission Grants NTI164 Orphan Drug Designation
Brief: Neurotech International Logs HY Loss From Ordinary Activities A$7.445 Mln
Brief: Neurotech International Says European Medicines Agency Issued Positive Opinion On Orphan Medicinal Product Designation Application Of NTI164
Brief: Neurotech International Signs Development Agreement For Cannabinoid Therapies